Investigators report results from the phase 3 randomized EMBARK trial.
Investigators analyzed survey results from 495 patients with newly diagnosed localized prostate cancer.
As cumulative occupational exposure to benzene-toluene-zylene increases, so does the risk for bladder cancer, new data suggest.
Swedish studies reveal significantly elevated risks for myocardial infarction, ischemic stroke, pulmonary embolism, and deep vein thrombosis.
New findings could have implications for the use of salvage therapies.
Trend may reflect increasing use of systemic immunotherapies as first-line treatments, according to investigators.
In a study, partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
A recent systematic review and meta-analysis provides the most up-to-date evidence for performance of triplet therapy compared with API-based doublets in mCSPC.
A single-institution study revealed that 37% of patients who underwent radical cystectomy experienced at least 1 additional intervention.
A second course of stereotactic body radiation therapy (SBRT) is an important therapeutic strategy to consider for men with recurrent oligometastatic prostate cancer after an initial course of SBRT, according to investigators.
